Corie Lok
Corie Lok is Xconomy's Special Projects Editor. Before joining Xconomy in 2017, she was at Nature for 12 years, first as an editor with the Careers section, then as a senior editor who launched Nature Network (a blogging and social networking website), and finally as an editor and features writer on Nature’s news team.
She earned a master’s degree in science journalism from Boston University and was a producer on the science and health beat for two national radio shows at the Canadian Broadcasting Corporation (CBC) in Toronto. She then spent two years covering emerging technologies with MIT Technology Review before arriving at Nature.
Corie is based in Boston and loves reading stories to her young son and playing the obscure but exciting winter sport of curling.
Recent posts
Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR editing. Beam’s promise of CRISPR-based therapeutics that... Read more »
After years of boom times, the U.S. biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government... Read more »
Seres Therapeutics was one of the first microbiome companies to form, back in 2010. And the Flagship Pioneering company was the first to go public. But today, faced with the... Read more »
An exciting new area of cell biology research that has emerged in only the last decade has already spawned a startup, which launches today with $60 million in Series A financing.... Read more »
[Updated 12:35pm ET with comments from Michael Gilman, Obsidian CEO, see below.] Bristol-Myers Squibb’s huge proposed buyout of Celgene earlier this month has left many in biotech circles concerned... Read more »
The partial government shutdown could soon become the longest shutdown in history, and biotech firms that have submitted regulatory filings are facing greater uncertainty about their future plans. More than 40... Read more »
Sage Therapeutics could soon win FDA approval for its postpartum depression (PPD) drug brexanalone, a 60-hour infusion supervised by a medical professional that could become the first drug to the... Read more »
Hearing loss drug development continues to attract investment, with Frequency Therapeutics announcing today that it has brought in $42 million in a Series B financing to help it move its treatment... Read more »
A new class of ovarian and breast cancer drugs that thwart a DNA repair mechanism ushered in a novel approach to treating cancer. The first PARP inhibitor was approved in 2014.... Read more »
The race to a peanut allergy treatment just got a little more interesting, with a major player, DBV Technologies withdrawing its application to the FDA for approval of its “Viaskin Peanut”... Read more »
Drugmakers are increasingly turning their attention toward fibrosis, the excessive growth of connective tissue that can lead to scarring and dysfunction of multiple organs including the lungs, liver and kidneys. In... Read more »
[Editor’s note: This is part of a series of posts sharing thoughts from industry and technology leaders about 2018 trends.]
It’s been almost a year since Harvard Pilgrim Health Care signed... Read more »
Omid Farokhzad has, as he says, “been around the block a few times” in biotech. The cancer nanomedicine researcher has cofounded a handful of companies that have tried to develop nanotech-based... Read more »
There’s at least one major pharmaceutical company that isn’t giving up yet on finding a drug for Alzheimer’s disease, despite a long trail of clinical flops. Eli Lilly is pairing up... Read more »
Brii Biosciences launched earlier this year with $260 million and a mission to find new medicines in infectious disease and other therapeutic areas and bring them to China. Today, the startup... Read more »
Ireland is the latest country to undertake an ambitious national project to sequence the genomes of a sizable chunk of its population. Genomics Medicine Ireland (GMI), a population genomics company based... Read more »
Most drugs target proteins in the cell, but the world of RNA has remained largely untapped by companies making chemical-based, or small-molecule drugs. That’s changing though—just in the last couple of... Read more »
[Updated October 30, 12:15pm ET with further comment, see below.] The immune systems of a large majority of people could already be primed to attack and possibly even disable... Read more »
[Updated 5:41pm ET with analyst note, see below.] When the Trump administration announced its blueprint for lowering prescription drug prices in May, many observers said it was too... Read more »
Centrexion Therapeutics is notable for focusing solely on developing non-opioid, non-addictive pain drugs—an area that biopharma companies have largely avoided. Now the Boston-based startup wants Wall Street’s help with... Read more »
